iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.4050
-0.0050 (-1.22%)
Aug 28, 2026, 5:07 PM SGT
iX Biopharma Balance Sheet
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 14.74 | 0.87 | 1.77 | 6.52 | 13.49 |
Short-Term Investments | - | 0.07 | 0.07 | 0.02 | 0.09 |
Cash & Short-Term Investments | 14.74 | 0.94 | 1.84 | 6.53 | 13.59 |
Cash Growth | 1475.94% | -49.27% | -71.79% | -51.91% | 118.65% |
Accounts Receivable | 1.97 | 1.03 | 1.29 | 1.25 | 0.5 |
Other Receivables | - | 0.91 | 1.63 | 1.8 | 1.48 |
Receivables | 1.97 | 1.94 | 2.92 | 3.05 | 1.98 |
Inventory | 1.19 | 0.92 | 1.38 | 0.96 | 0.91 |
Prepaid Expenses | - | 0.41 | 0.44 | 0.44 | 0.37 |
Other Current Assets | 0.71 | - | - | - | - |
Total Current Assets | 18.61 | 4.21 | 6.59 | 10.98 | 16.84 |
Property, Plant & Equipment | 7.13 | 6.72 | 7.61 | 8.22 | 7.72 |
Long-Term Investments | - | - | 0.01 | 3.87 | 2.26 |
Goodwill | - | 0.27 | 0.29 | 0.29 | 0.31 |
Other Intangible Assets | 0 | - | 0 | - | 0.04 |
Long-Term Deferred Tax Assets | - | - | - | 1.38 | 1.28 |
Other Long-Term Assets | 0.13 | 0.09 | 0.13 | 0.19 | 0.07 |
Total Assets | 25.88 | 11.28 | 14.62 | 24.93 | 28.52 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 4.16 | 1.3 | 1.26 | 0.4 | 0.22 |
Accrued Expenses | 0.12 | 2.99 | 2.87 | 2.81 | 2.31 |
Current Portion of Long-Term Debt | 5.22 | 4.08 | 2.49 | 2.75 | 3.29 |
Current Portion of Leases | 0.31 | 0.27 | 0.39 | 0.44 | 0.24 |
Current Income Taxes Payable | 0.19 | 0.18 | 0.17 | 0.73 | 1.76 |
Other Current Liabilities | - | 0.14 | 0.21 | 0.05 | 0.04 |
Total Current Liabilities | 10.01 | 8.98 | 7.38 | 7.18 | 7.86 |
Long-Term Debt | 0.12 | 1.47 | 2.18 | 0.57 | 0.88 |
Long-Term Leases | 0.15 | 0.08 | 0.14 | 0.58 | - |
Other Long-Term Liabilities | 0.2 | 0.39 | 0.58 | 0.76 | 0.04 |
Total Liabilities | 10.48 | 10.92 | 10.28 | 9.08 | 8.77 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 125.67 | 100.83 | 97.45 | 97.23 | 94.18 |
Retained Earnings | -114.9 | -107.12 | -96.98 | -86.18 | -76.57 |
Comprehensive Income & Other | 4.62 | 6.65 | 3.87 | 4.8 | 2.13 |
Shareholders' Equity | 15.4 | 0.37 | 4.34 | 15.85 | 19.74 |
Total Liabilities & Equity | 25.88 | 11.28 | 14.62 | 24.93 | 28.52 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 5.8 | 5.9 | 5.2 | 4.34 | 4.41 |
Net Cash (Debt) | 8.93 | -4.97 | -3.36 | 2.2 | 9.18 |
Net Cash Growth | - | - | - | -76.08% | 363.97% |
Net Cash Per Share | 0.01 | -0.01 | -0.00 | 0.00 | 0.01 |
Filing Date Shares Outstanding | 1,068 | 887.96 | 883.34 | 766.3 | 764.9 |
Total Common Shares Outstanding | 1,068 | 887.96 | 768.32 | 766.3 | 751.19 |
Working Capital | 8.61 | -4.77 | -0.8 | 3.8 | 8.99 |
Book Value Per Share | 0.01 | 0.00 | 0.01 | 0.02 | 0.03 |
Tangible Book Value | 15.39 | 0.1 | 4.05 | 15.56 | 19.4 |
Tangible Book Value Per Share | 0.01 | 0.00 | 0.01 | 0.02 | 0.03 |
Land | 2.54 | 2.38 | 2.57 | 2.56 | 2.73 |
Buildings | 1.72 | 1.61 | 1.74 | 1.74 | 1.85 |
Machinery | 7.25 | 6.7 | 6.99 | 6.71 | 6.6 |
Leasehold Improvements | 0.75 | 0.71 | 0.76 | 0.74 | 0.64 |